Wednesday, July 8, 2026

Patent intelligence · US

US 12171761

Vilazodone inclusion complexes, compositions and preparation thereof

granted A61KA61K31/496A61K47/40A61K9/2009
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 18
Applicant portfolio 121
Patent details — US 12171761
Jurisdiction
US
Status
granted
Grant date
Dec 24, 2024
Expiration
Dec 19, 2044
Claims
24
CPC classes
A61K, A61K31/496, A61K47/40, A61K9/2009
View on Google Patents ↗

Quick answer

US 12171761 (Vilazodone inclusion complexes, compositions and preparation thereof) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
24
CPC classes
A61K, A61K31/496, A61K47/40, A61K9/2009, A61K9/2018, A61K9/2027

More from SUNSHINE LAKE PHARMA CO., LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12428432

    Thienopyrimidine derivatives having stereo configurations and use thereof in medicine

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Sep 25, 2045

    granted
  2. US 12428389

    Diarylamide compound and application thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Sep 25, 2045

    granted
  3. US 12384853

    Anti-HER2/PD1 bispecific antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires Aug 7, 2045

    granted
  4. US 12324812

    Glucopyranosyl derivatives and their uses

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Jun 5, 2045

    granted
  5. US 12319748

    Antibody binding to human HER2 and preparation method and use thereof

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires May 29, 2045

    granted
  6. US 12312348

    RET inhibitors, pharmaceutical compositions and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires May 22, 2045

    granted
  7. US 12269886

    Tetravalent bispecific antibody against PD-1 and PD-L1

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires Apr 3, 2045

    granted
  8. US 12258317

    Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Mar 20, 2045

    granted

Frequently asked questions

What is US patent 12171761?

US 12171761 (Vilazodone inclusion complexes, compositions and preparation thereof) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12171761?

SUNSHINE LAKE PHARMA CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 121 pharmaceutical patents for this assignee.

When does US 12171761 expire?

Our index shows an expiration date of Dec 19, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.